Amyotrophic Lateral Sclerosis (ALS) – Opportunity Analysis and Forecasts to 2029

2020-09-15
Price :
Published : Sep-2020
No. of Pages : 128

Amyotrophic Lateral Sclerosis (ALS) – Opportunity Analysis and Forecasts to 2029

Summary

Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary – which is known as FALS (Familial ALS) or idiopathic – known as SALS (sporadic ALS).

ALS current treatment includes only two disease-modifying drugs: Sanofi’s Rilutek (riluzole) and Mitsubishi Tanabe’s Radicava/Radicut (edaravone). Two reformulations of riluzole were approved recently: ITF Pharma’s Tiglutik (riluzole oral suspension) in 2018 and Aquestive Therapeutics’ Exservan (riluzole oral film) in 2019. Both reformulations address problems of advanced-stage ALS patients who have difficulty in swallowing (dysphagia). Tiglutik is the first liquid formulation of riluzole to launch in the market; it can also be administrated via percutaneous endoscopic gastrostomy tubes (PEG-tubes), while Exservan is a thin oral film that dissolves on the tongue without the need of any muscle action.

GlobalData estimates that sales of drugs in the ALS market were approximately $282M in 2019 in the 8MM. The US was the largest market, with sales of $197M, representing 70% of all sales from the 8MM. The highest-selling drug in the market was Mitsubishi’s Radicava (edaravone), a free radical scavenger, which generated sales of $162M in the 8MM in 2019.

Global sales in the ALS market are expected to grow to $1.04B by 2029, at a Compound Annual Growth Rate (CAGR) of 13.9%.

Key Highlights

– Currently, the only treatment options for ALS are Rilutek (8MM) and Radicava/Radicut (US, Japan, and Canada), neither of which can stop nor significantly slow the progression of the disease. At best, these drugs may increase a patient’s life span by up to six months.
– GlobalData anticipates that nine late stage pipeline drugs will launch over the forecast period. These drugs will be used as adjunctive therapies to Rilutek, Tiglutik, Exservan, and Radicava. They aim to address some of the longstanding clinical unmet needs and are expected to be the main driver of growth in the ALS market across the 8MM.
– Biogen’s BIIB067 (tofersen) antisense therapy is forecast to be a major player in the ALS market; due to its high ACOT despite its limited patient pool.
– There are few therapies in the pipeline that aim at addressing major unmet needs, they will all have to translate promising Phase II results into Phase III successes, which KOLs have stated has been a stumbling block for previous therapies.
– Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which are potential curative agents, or extend patient survival more than the current SOC.

Key Questions Answered

– What are the key ALS treatments in 2019?
– When will the late stage pipeline products launch, and how will it affect drug sales and the overall ALS market in the 8MM?
– Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

– Overview of ALS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
– Annualized ALS therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (familial and sporadic) forecast from 2019 to 2029.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ALS therapeutics market
– Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ALS therapy. The most promising candidates in Phase IIb and Phase III development are profiled.
– Analysis of the current and future market competition in the global ALS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global ALS therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ALS therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Meningococcal Vaccines – Global Drug Forecast and Market Analysis to 2029

Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2029 Summary Meningococcal disease is an infection caused by Neisseria meningitidis bacteria, and, although relatively rare, is widely feared because of its high mortality rate even in otherwise healthy individuals. Serogroups A, B, C, W, and Y are the most common meningococcal types in the nine major markets (9MM) covered in this report (US, France, Germany, Italy, Spain, UK, Argentina, Brazil, and China), and immunization of high-risk groups such as infants and adolescents provides the best protection against the infection. Immunization with conjugated meningococcal serogroup C (MenC) is routinely recommended for infants in the 5EU and Brazil, and immunization against serogroup ACWY (MenACWY vaccines) is recommended i......
$10995

Invasive Meningococcal Disease – Epidemiology Forecast to 2029

Invasive Meningococcal Disease - Epidemiology Forecast to 2029 Summary Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis). N. meningitidis is an encapsulated gram-negative bacterium that exists without complication in roughly 5-11% of adults and up to 25% of adolescents. However, if the bacterium moves beyond the nasopharynx and invades body tissue, serious illness can arise, usually in the form of meningitis or septicemia. Symptoms of disease can include fever, headache, stiff neck, nausea, photophobia, and fatigue, among others. The bacterium is spread by respiratory droplets through close or prolonged contact with an infected person and is not as contagious as the common cold or flu. In 2019, there wer......
$3995

Ulcerative Colitis – Epidemiology Forecast to 2029

Ulcerative Colitis - Epidemiology Forecast to 2029 Summary Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the large intestine and the rectum. The inflammation occurs only in the innermost layer of the lining of the intestine. In UC, ulcers develop on the surface of the bowel lining; these may bleed and produce mucus. If the inflammation is confined to rectum, it is called proctitis (Crohn's and Colitis Foundation of America, 2014; Crohn's and Colitis UK, 2019). UC can occur at any age, though most people are diagnosed in their mid-thirties. Men and women are equally likely to be affected, but older men are more likely to be diagnosed than older women. GlobalData epidemiologists utilized historical data obtained from peer-reviewed......
$3995

Contract Dose Manufacturing Industry by the Numbers – Composition, Size, Market Share and Outlook – 2020 Edition

Contract Dose Manufacturing Industry by the Numbers - Composition, Size, Market Share and Outlook - 2020 Edition Summary This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2020, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management. This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalData's Pharma Intelligence Center Contract Service Providers Database) this analysis is driven by a ......
$4995

Egypt Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report, "Egypt Healthcare, Regulatory and Reimbursement Landscape - CountryFocus". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Egypt. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalDa......
$1995

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective

Coronavirus Disease 2019 (COVID-19) Impact on Telemedicine, a Physician Perspective Summary Telemedicine is the use of electronic communication for the delivery of remote clinical care. It has been recognized as a critical strategy during the ongoing coronavirus disease 2019 (COVID-19) pandemic to limit the risk of person-to-person transmission of the virus as social distancing has become the norm. It is widely anticipated that COVID-19 may be the tipping point for telemedicine as the full potential of the technology is increasingly realized by patients, healthcare systems, and payers. As a result of the pandemic, regulations and policies governing reimbursement and use of telemedicine have changed significantly, leading to expanded access and an unprecedented demand for these services.......
$1495

Greece Healthcare, Regulatory and Reimbursement Landscape – CountryFocus

Greece Healthcare, Regulatory and Reimbursement Landscape - CountryFocus Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Greece". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glob......
$1995

Mania Disease – Global Clinical Trials Review, H2, 2020

Mania Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Mania Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Mania Clinical trials scenario. This report provides top line data relating to the clinical trials on Mania. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinical trials database. Clinical trials are colla......
$2500

Duchenne Muscular Dystrophy Disease – Global Clinical Trials Review, H2, 2020

Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Duchenne Muscular Dystrophy Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Critical Limb Ischemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Critical Limb Ischemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's propr......
$2500

Gestational Diabetes Disease – Global Clinical Trials Review, H2, 2020

Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Gestational Diabetes Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Gestational Diabetes Clinical trials scenario. This report provides top line data relating to the clinical trials on Gestational Diabetes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy